- Concurrently, the Company accepted the resignations of Dr.
Colin Goddard and Mr. Joacim Borg
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a
clinical-stage immunotherapy and Antibody Drug Conjugate
biopharmaceutical company, today announced the appointments of
Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as
independent members of the Company’s Board of Directors.
Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years
of biopharmaceutical executive decision-making experience to the
Company, with a specific focus in commercializing biologic
products.
“OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr.
Jarry to our Board of Directors,” said Paul Romness, MHP, Chairman
& CEO of OS Therapies. “Ms. McKean Dieser brings a deep
execution experience in regulatory, pricing, commercialization, and
patient engagement, while Mr. Jarry brings significant business
development and fundraising expertise & relationships to the
Company. As we continue preparations to engage FDA regarding our
potentially pivotal trial of our cancer immunotherapy OST-HER2
seeking to prevent metastasis in resected, recurrent osteosarcoma,
we are building up our internal infrastructure to prepare for
regulatory approval and commercial launch in the United States,
while evaluating strategic partnerships to bring the therapy to
market outside the United States. Ms. McKean Dieser and Mr. Jarry
are well positioned to help us achieve these objectives.”
Mr. Romness added, “We would like to thank Dr. Colin Goddard and
Mr. Joacim Borg for the years of service to the Company, especially
for their guidance in helping OS Therapies transition into a public
company.”
Ms. McKean Dieser holds a global role as Vice President, Head of
Legal Patient Evidence of UCB, Inc., a subsidiary of UCB, S.A., a
global biopharmaceutical company focused on the discovery and
development of innovative medicines and solutions to transform the
lives of people living with severe diseases of the immune system or
the central nervous system. At UCB, she leads a team of attorneys
supporting UCB’s global assets, global payer functions, and
regulatory, medical and patient communities, including clinical
development. Ms. McKean Dieser was formerly a member of the AbbVie
Inc. legal team providing global product support for the immunology
and oncology franchises and was the government pricing lawyer for
all pharmaceutical and combination products from May 2013 to July
2016. Prior to joining the pharmaceutical industry, Ms. McKean
Dieser practiced corporate law in Atlanta, Georgia at two
nationally recognized law firms. She earned her J.D. degree from
The Catholic University Columbus School of Law and is admitted to
practice law in the states of Georgia and Illinois. Prior to
receiving her law degree, Ms. McKean Dieser received an M.A. in
Public Administration from the University of Maryland, European
Division and a B.A. degree in English Literature from Duquesne
University. Ms. McKean Dieser lost her son, Edward, to Osteosarcoma
in January 2024 at the age of 21.
“I am deeply grateful that OS Therapies’ mission is to bring to
market the first new osteosarcoma treatment in over 40 years,” said
Ms. McKean Dieser. “As a newly appointed director, I will focus on
helping management implement its regulatory and commercialization
plan so that OST-HER2 can ultimately reach the patients and
families desperate for new solutions in this very hard to treat
childhood cancer.”
“OS Therapies represents a unique opportunity to bring to market
a novel cancer immunotherapy in the rare pediatric disease of
osteosarcoma that could thereafter potentially change the standard
of care in HER2 expressing cancers given its novel mechanism of
action,” said Mr. Olivier Jarry, newly appointed independent Board
member of OS Therapies. “The potential to receive a priority review
voucher following an approval in osteosarcoma that could then be
sold to help fund the commercialization of OST-HER2 in osteosarcoma
and potential label-expanding clinical trials into breast cancer,
colorectal cancer and/or other solid tumors is compelling from both
an investment and product development perspective. I am excited to
help play an important role in supporting the Company to achieve
its strategic objectives.”
Mr. Jarry is the Co-founder and Chief Executive Officer of
Libera Bio S.L., a private Spanish biopharmaceutical company
devoted to the development of a new class of precision therapeutics
to address intracellular cancer targets. He also serves as the
Chief Operating Officer of Advantage Therapeutics Inc., an
investigational-stage company focused on the diseases of aging, and
as Chief Financial Officer of Rational Vaccines, Inc., an
investigational-stage infectious disease company. Mr. Jarry
previously served as President and Chief Commercial Officer of
DarioHealth (Nasdaq: DRIO) from October 2017 until January 2020.
Between 2015 and 2016, he served as Senior Vice President of the
Consumer Sector and Officer at Intrexon Corp. (NYSE: XON), a
biotechnology company focused on engineering biological systems to
enable DNA-based control over the function and output of living
cells. Prior to Intrexon, from 2011 to 2012, Mr. Jarry served as
the Head of Strategy, Operations and Market Access, focusing on
Emerging Markets, for Bristol-Myers Squibb (NYSE: BMY), where he
oversaw the product launch and growth of innovative medicines
relating to oncology, virology, rheumatology, cardiovascular and
diabetes. Prior to that, Mr. Jarry served as the Global Business
Unit Head of Bayer Diabetes Care, a division of Bayer HealthCare
Pharmaceuticals LLC and in several leadership roles at Novartis
International AG (NYSE: NVS). Mr. Jarry holds a M.Sc. degree from
Ecole Centrale de Paris, a MEng. degree from Délégation Générale
pour l’Armement, and a Trium Executive MBA degree jointly awarded
by NYU Stern School of Business, London School of Economics and
Political Science and Hautes Études Commerciales Paris.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the
identification, development and commercialization of treatments for
Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s
lead asset, is an immunotherapy leveraging the immune-stimulatory
effects of Listeria bacteria to initiate a strong immune response
targeting the HER2 protein. The Company has completed enrollment
for a 41-patient Phase 2b clinical trial of OST-HER2 in resected,
recurrent osteosarcoma, with results expected in the fourth quarter
of 2024. OST-HER2 has completed a Phase 1 clinical study primarily
in breast cancer patients, in addition to showing strong
preclinical efficacy data in various models of breast cancer.
OST-HER2 has been conditionally approved by the U.S. Department of
Agriculture for the treatment of canines with osteosarcoma. In
addition, OS Therapies is advancing its next generation Antibody
Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This
platform leverages the Company’s proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker.
For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
forward-looking statements within the meaning of the federal
securities laws. These forward-looking statements and terms such as
“anticipate,” “expect,” “intend,” “may,” “will,” “should” or other
comparable terms involve risks and uncertainties because they
relate to events and depend on circumstances that will occur in the
future. Those statements include statements regarding the intent,
belief or current expectations of OS Therapies and members of its
management, as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, including those described
under the section entitled “Risk Factors” of our Registration
Statement on Form S-1 declared effective by the Securities and
Exchange Commission (the “SEC”) on July 31, 2024, as well as any of
our periodic reports filed with the SEC, and that actual results
may differ materially from those indicated by such forward-looking
statements. Any forward-looking statements contained in this press
release speak only as of the date hereof, and, except as required
by the federal securities laws, OS Therapies specifically disclaims
any obligation to update any forward-looking statement, whether as
a result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241028955556/en/
Corporate and Media Contact: Jack Doll 410-297-7793
irpr@ostherapies.com
OS Therapies (AMEX:OSTX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
OS Therapies (AMEX:OSTX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
